In vitro diagnostic (IVD) development for Lyme disease involves creating accurate and reliable tools. Our company is committed to advancing the field of Lyme disease diagnostics by conducting in-depth research on Lyme disease diagnostic biomarkers and enhancing effective Lyme disease management through the design of innovative IVD kits and devices.
Overview of Lyme Disease
Lyme disease is an infection caused by the Borrelia bacteria, mainly spread through the bites of ticks. After the tick bite, the bacteria enter the bloodstream, causing the typical symptoms associated with the disease, such as rash, fever, joint pain, etc. Timely diagnosis is crucial for effective therapeutics and to prevent the infection from advancing to a severe stage.
Fig. 1 The structure of Borrelia burgdorferi. (Kurokawa, Cheyne, et al., 2020)
Diagnostic Biomarkers for Lyme Disease
Lyme disease presents a diagnostic challenge due to its diverse range of symptoms and the potential for misdiagnosis. Having specific biomarkers for Lyme disease can significantly improve diagnostic accuracy and help differentiate it from other conditions with similar symptoms. Several biomarkers have been investigated for their utility in diagnosing Lyme disease.
Antibodies
Borrelia-specific antibodies, particularly Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies, serves as a critical diagnostic marker for Lyme disease. IgM antibodies commonly indicate an infection in its early stages, while the presence of IgG antibodies suggests a previous or later-stage infection.
Antigens
Borrelia burgdorferi-specific antigens serve as direct markers for the presence of the bacterium. Flagellar antigens and surface protein antigens are significant antigens in diagnostic testing. Antigen testing offers the advantage of directly identifying the pathogen in the sample without the requirement to generate antibodies.
DNA
Detection of Borrelia burgdorferi DNA in samples is a sensitive and specific method for diagnosing Lyme disease. Polymerase chain reaction (PCR) assays targeting specific regions of the Borrelia genome can amplify and detect bacterial DNA present in blood, tissue, or cerebrospinal fluid samples.
IVD Kits for Lyme Disease
The development of in vitro diagnostics (IVD) for Lyme disease encompasses the creation of precise and dependable tools for identifying the presence of Borrelia burgdorferi in a sample. IVD kits are integral to the diagnosis of Lyme disease, offering healthcare providers reliable methods for detecting Borrelia burgdorferi infection, confirming diagnoses, and guiding therapeutic decisions.
| Kits |
Applications |
Detection Methods |
| Borrelia Burgdorferi DNA Test Kit |
Qualitative detection of Borrelia burgdorferi DNA. |
PCR |
| Borrelia BurgdorferiAntibody Test Kit |
Detection of Borrelia burgdorferi-specific antibodies (IgM and IgG) in serum samples. |
ELISA |
| Lyme Disease Rapid Antigen Test Kit |
Point-of-care testing for Borrelia burgdorferi antigen. |
Immunochromatography |
Our Services
Our company is committed to pioneering innovative
IVD solutions for Lyme disease. Our services encompass the development of IVD kits for
antigen,
antibody,
DNA, and
microbial detection, facilitating accurate and swift diagnosis of Lyme disease. Our mission is to reshape the landscape of Lyme disease diagnostics by creating state-of-the-art
IVD products.
IVD Product Development Services
Furthermore, our services extend to
point-of-care testing (POCT) and
companion diagnostic development tailored for Lyme disease, aiding in the rapid detection and personalized therapies of the infectious disease. If you are interested in our services, please feel free to
contact us for more details and quotation information of related services.
Reference
- Kurokawa, Cheyne, et al. "Interactions between Borrelia burgdorferi and ticks." Nature Reviews Microbiology 18.10 (2020): 587-600.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
